Emsam is a drug owned by Somerset Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 12, 2018. Details of Emsam's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7150881 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
Jun, 2018
(6 years ago) |
Expired
|
| US7638140 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May, 2018
(6 years ago) |
Expired
|
| US7070808 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Emsam's patents.
Latest Legal Activities on Emsam's Patents
Given below is the list of recent legal activities going on the following patents of Emsam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 31 Jan, 2022 | US7638140 |
| Maintenance Fee Reminder Mailed Critical | 16 Aug, 2021 | US7638140 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Dec, 2017 | US7070808 |
| Correspondence Address Change Critical | 25 Apr, 2014 | US7638140 |
| Correspondence Address Change Critical | 25 Apr, 2014 | US7070808 |
| Post Issue Communication - Certificate of Correction | 01 Feb, 2011 | US7638140 |
| Recordation of Patent Grant Mailed Critical | 29 Dec, 2009 | US7638140 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Dec, 2009 | US7638140 |
| Issue Notification Mailed Critical | 09 Dec, 2009 | US7638140 |
| Application Is Considered Ready for Issue Critical | 16 Nov, 2009 | US7638140 |
US patents provide insights into the exclusivity only within the United States, but Emsam is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emsam's family patents as well as insights into ongoing legal events on those patents.
Emsam's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Emsam's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 12, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Emsam Generics:
There are no approved generic versions for Emsam as of now.
Alternative Brands for Emsam
There are several other brand drugs using the same active ingredient (Selegiline) as Emsam. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch |
|
About Emsam
Emsam is a drug owned by Somerset Pharmaceuticals Inc. Emsam uses Selegiline as an active ingredient. Emsam was launched by Somerset in 2006.
Approval Date:
Emsam was approved by FDA for market use on 27 February, 2006.
Active Ingredient:
Emsam uses Selegiline as the active ingredient. Check out other Drugs and Companies using Selegiline ingredient
Dosage:
Emsam is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 6MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |
| 12MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |
| 9MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |